Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. filed an 8-K on March 23, 2026 disclosing that it submitted a Certificate of Correction (CoC) with the State of Delaware to its Certificate of Designation of Series B Preferred Stock (part of the company’s Certificate of Incorporation). The CoC corrects a scrivener’s error. The full text of the Certificate of Correction is attached to the filing as Exhibit 3.1 and is incorporated by reference.

Key Details

• Filing: Form 8-K filed March 23, 2026 (Item 5.03).
• Action: Certificate of Correction to the Certificate of Designation of Series B Preferred Stock filed in Delaware.
• Purpose: To correct a scrivener’s error in the Certificate of Designation.
• Documentation: The CoC text is included as Exhibit 3.1 to the 8-K.

Why It Matters
This is an administrative/legal housekeeping filing that clarifies the company’s charter paperwork for the Series B preferred stock. The 8-K states the item is a correction of a scrivener’s error and provides the corrected text; it does not describe other substantive changes to rights or economic terms. Investors with exposure to or interest in Ensysce’s Series B preferred shares should review Exhibit 3.1 to see the exact correction and watch for any future filings if further amendments or disclosures are made.